卡托普利(Captopril) - 药物靶点：ACE_在研适应症：原发性高血压，恶性高血压，肾血管性高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid、Captopril (JP17/USP/INN)、Captopryl

+ [19]

靶点

ACE

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)

治疗领域

心血管疾病内分泌与代谢疾病泌尿生殖系统疾病

在研适应症

原发性高血压恶性高血压肾血管性高血压+ [5]

非在研适应症

新型冠状病毒感染左心室功能不全

原研机构

Daiichi Sankyo Co., Ltd.

在研机构

Daiichi Sankyo Co., Ltd.

常州制药厂有限公司成都倍特得诺药业有限公司

+ [2]

非在研机构

Kafrelsheikh University

最高研发阶段批准上市

首次获批日期

日本 (1980-01-01),

糖尿病肾病心脏衰竭高血压+ [1]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C9H15NO3S

InChIKeyFAKRSMQSSFJEIM-RQJHMYQMSA-N

CAS号62571-86-2

关联

94

项与卡托普利相关的临床试验

NCT05293158 / Not yet recruitingN/AIIT

Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma

In the current literature, infection with the hepatitis B virus (HBV) is described as one of the main risk factors for the development of hepatocellular carcinoma (HCC).
According to the current study situation, the Hepatitis B surface antigen (HBsAg) is considered as an important marker, since low levels and sero-clearance of HBsAg are both correlated with a lower risk of HCC development / recurrence.Currently there is no treatment option available that efficiently targets HBsAg. Besides neutralizing infectious HBV virions, Hepatitis B immunoglobulins (HBIG) can directly bind and neutralize extracellular HBsAg/SVPs, and even intracellular HBsAg targeting is reported. In addition, HBIGs can initiate effector-cell attack (via antibody-dependent cellular cytotoxicity, ADCC) towards infected hepatocytes.
The potential benefit of HBIGs in the HCC context is further underlined by recent evidence for the ability of HBIGs to reduce the viability, proliferation, and self-renewal of tumor-initiating cells (TICs) - isolated from HBV-HCC patients - accompanied by downregulation of stemness markers, e.g., OCT-4.According to the current study situation, the use of HBIGs significantly reduces the risk of HBV reinfection after transplantation and improves the results of liver transplantation in patients with chronic HBV infection. The potential benefit of treating HBV-HCC patients on the LTx (liver transplantation) waiting list with hepatitis B immunoglobulin is the possible stop or inhibition of tumor progression while waiting for an LTx. So far there is no clinical evidence of this.
Mechanistically, hepatitis B immunoglobulin could occur through neutralization of circulating HBsAg, which is an important driver of an immunosuppressive environment in HBV patients, and possibly through direct effects against HBV HCC tumor cells (through antibody-dependent cellular cytotoxicity, ADCC). Therefore, the idea behind preoperative HBIG administration before liver transplantation is to reduce the rate of patients in whom a transplantation would no longer have been possible due to tumor progression. Thus, due to tumor progression in HBV-positive HCC-patients there is a monthly drop-out from the waiting list of about 4%.
The basic idea behind the treatment of HBV-HCC patients before tumor resection with hepatitis B immunoglobulin is to potentially stop or positively influence tumor progression through the effects mentioned above, in the time between diagnosis and resection.
Zhou et al. (2015) have shown a connection between HBsAg levels and HCC relapses after resection, although the exact role of HBsAg is still unclear. In no case will the treatment postpone the time of tumor resection, as only patients are considered who, for clinical reasons, can expect a certain time until resection. The present proof of concept study aims to quantify HBsAg reduction due to preoperative administration of HBIGs in HBV-positive HCC-patients and serve as a template for future multicentre clinical trials.

开始日期2024-11-01

申办/合作机构

Medizinische Universität Graz

NCT04629651 / Withdrawn临床1/2期

Phase I/II Prospective Trial Investigating the Safety and Efficacy of Captopril Use on the Degree of Marrow Fibrosis in Patients With Primary or Secondary Bone Marrow Fibrosis/Myeloproliferative Neoplasms

The purpose of this study is to evaluate the safety and tolerability of captopril and evaluate the effectiveness captopril as measured by changes in the grade of bone marrow scar tissue. The change in spleen size by ultrasound will also be measured.

开始日期2024-04-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT06292091 / Completed临床1期IIT

An Open-label, Fixed-sequence, 3-period Crossover Exploratory Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril in Healthy Male Volunteers

The aim of this study is to evaluate the effect of urine acid-base disequilibrium on the pharmacokinetics of captopril in healthy male volunteers.

开始日期2024-02-28

申办/合作机构

Seoul National University Hospital

100 项与卡托普利相关的临床结果

登录后查看更多信息

100 项与卡托普利相关的转化医学

登录后查看更多信息

100 项与卡托普利相关的专利（医药）

登录后查看更多信息

18,737

项与卡托普利相关的文献（医药）

2024-06-01·Bioelectrochemistry (Amsterdam, Netherlands)

Low efficiency of cathodic protection in marine tidal corrosion of X80 steel in the presence of Pseudomonas sp.

Article

作者: Li, Cong ; Wang, Qin ; Li, Zhi ; Su, Hui ; Tan, Zhuowei ; Wu, Tangqing ; Zhou, Xiaobao

Owing to the effects of seawater erosion, dry/wet cycles, dissolved oxygen and microorganisms, the corrosion of steel in marine tidal environments is a serious threat to the safe and stable operation of marine equipment and facilities. Among them, microbiologically influenced corrosion (MIC) of steel has received increasing attention. Cathodic protection (CP) is frequently used to control the corrosion of offshore steel structures. However, in the presence of microorganisms, implementation of CP and its specific effects remain controversial. In this study, the influence of Pseudomonas sp. on the CP efficiency of Zn sacrificial anodes (ZnSAs) during the tidal corrosion of X80 steel was studied. The results showed that CP efficiency exceeded 92% in an abiotic tidal environment. However, in the biotic tidal environment, Pseudomonas sp. significantly reduced the CP efficiency. Pseudomonas sp. and its biofilm promoted the corrosion of steel under CP, inhibited the formation of a complete calcareous deposit layer, which weakened the CP efficiency of ZnSA in the marine tidal environment.

2024-06-01·Food chemistry

Unraveling the effect of combined heat and high-pressure homogenization treatment on the improvement of chickpea protein solubility from the perspectives of colloidal state change and structural characteristic modification

Article

作者: Chen, Xing ; Yuan, Jing-Jing ; Bai, Yan-Hong ; Zhang, Ya-Ru ; Wang, Jia-le ; Chen, Bo ; Wang, Yu ; Li, Ke

Chickpea protein (CP) is a promising plant protein ingredient, but the poor solubility has limited its broad application. In this study, heating followed by high-pressure homogenization (HPH) was used to improve the solubility of CP. The results showed that combined heat (80℃, 30 min) and HPH (80 MPa, 2 cycles) treatment exhibited an additive effect in improving the solubility of CP. This improvement could be attributed to the dissociation and the rearrangement of large insoluble protein aggregates into small-sized soluble protein aggregates, the increased exposure of hydrophobic residues and reactive sulfhydryl groups, the transformation of α-helices to β-sheets and β-turns. Moreover, the 11S subunits of CP could form reinforced disulfide covalent cross-links under heating + HPH, which may provide steric hindrance preventing the reassembly of large protein bodies. This work proposes an interesting approach to enhance the physicochemical properties of CP for tailoring techno-functional plant protein ingredients in food formulations.

2024-04-15·Journal of computational chemistry

Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study

Article

作者: Scoditti, Stefano ; Shoeib, Tamer ; Sicilia, Emilia ; Dabbish, Eslam ; Shehata, Mohammed N I ; Ibrahim, Mahmoud A A ; Ritacco, Ida

Abstract:

The oxazaphosphorine cyclophosphamide (CP) is a DNA‐alkylating agent commonly used in cancer chemotherapy. This anticancer agent is administered as a prodrug activated by a liver cytochrome P450‐catalyzed 4‐hydroxylation reaction that yields the active, cytotoxic metabolite. The primary metabolite, 4‐hydroxycyclophosphamide, equilibrates with the ring‐open aldophosphamide that undergoes β‐elimination to yield the therapeutically active DNA cross‐linking phosphoramide mustard and the byproduct acrolein. The present paper presents a DFT investigation of the different metabolic phases and an insight into the mechanism by which CP exerts its cytotoxic action. A detailed computational analysis of the energy profiles describing all the involved transformations and the mechanism of DNA alkylation is given with the aim to contribute to an increase of knowledge that, after more than 60 years of unsuccessful attempts, can lead to the design and development of a new generation of oxazaphosphorines.

57

项与卡托普利相关的新闻（医药）

2024-06-21

·drugs

Angiotensin Receptor Blocker Use Linked to Lower Incidence of Epilepsy

FRIDAY, June 21, 2024 -- For patients with hypertension, angiotensin receptor blockers (ARBs) are associated with a reduced incidence of epilepsy compared with other antihypertensive medications, according to a study published online June 17 in JAMA Neurology . Xuerong Wen, Ph.D., from the University of Rhode Island in Kingston, and colleagues conducted a retrospective cohort study to examine the association between ARB use and epilepsy incidence in subgroups of U.S. patients with hypertension. Patients who received ARBs were propensity score (PS)-matched to those who received angiotensin-converting enzyme inhibitors (ACEIs), β-blockers, calcium channel blockers (CCBs), or a combination of these medications. Of the participants, 309,978 received ARBs, 807,510 received ACEIs, 695,887 received β-blockers, and 448,589 received CCBs; the 1:1 PS-matched subgroups included 619,858 patients for ARB versus ACEI, 619,828 patients for ARB versus β-blocker, and 601,002 patients for ARB versus CCB. The researchers found that the incidence of epilepsy was reduced with use of ARBs versus ACEs, β-blockers, and a combination of other antihypertensive classes (adjusted hazard ratios, 0.75, 0.70, and 0.72, respectively). In subgroup analyses, the investigators observed a significant association between ARB use (mainly losartan) and epilepsy incidence in patients with no preexisting history of stroke or cardiovascular disease. "Further pharmacological studies, including randomized clinical trials, are needed to establish antiepileptogenic properties of antihypertensive medications," the authors write. Two authors disclosed ties to the pharmaceutical and medical device industries.

临床结果

2024-05-14

·PRNewswire

CardioPharma Announces Issuance of Global Patent to Mitigate the World's Top Killer

WILMINGTON, N.C., May 14, 2024 /PRNewswire/ -- CardioPharma Inc. (the "Company"), a specialty pharmaceutical company focused on drug development for cardiovascular diseases, announced that on August 29, 2023, the United States Patent and Trademark Office ("USPTO") issued US Patent 11,737,988 B2 entitled "Anti-Hypertensive and Cholesterol-Lowering Fixed-Dose Combination and Method of Manufacture." Additional patents covering the subject matter of the '988 Patent have been granted in South Africa in 2022 and Australia, Armenia, Belarus, and the Russian Federation in 2024. Three further patents have been accepted in Canada, New Zealand, and Israel and will issue in the near future. In addition to the foregoing, CardioPharma is pursuing additional patents in major markets throughout the world, all of which together will bolster CardioPharma's global presence for the products covered by the patent grants. The 20-year term for all of the patents runs through April 17, 2039. CardioPharma Pipeline CardioPharma's pipeline products contain some of the world's most consumed, individually dispensed medications for the prevention and treatment of cardiovascular disease. The lead product, CardiaPill® is a unique formulation combining a cholesterol modifying agent ("statin"), an Angiotensin-converting-enzyme inhibitor (ACE Inhibitor) and anti-platelet agent. Statins moderate cholesterol levels and include products such as Lipitor®, Zocor®, Pravachol®; and Crestor®. ACE inhibitors reduce blood pressure and include products such as Altace®, Lotensin®, Capoten® and Accupril®. Pipeline products also include combinations using Angiotensin II Receptor Blockers (ARBs) as well as different statins and other anti-platelet agents. Simplicity of dosing, improved adherence and significant cost benefits for patients, providers and payors around the world are among the many compelling and well-documented benefits that make these inexpensive products so anticipated. About CardioPharma CardioPharma (), Inc. is a specialty pharmaceutical company focused on patent-protected combinatorial cardiovascular medications. CardioPharma's goal is to create drugs that make it easier and more cost-effective for doctors and their patients to reduce the morbidity and mortality of the world's number one killer – cardiovascular disease. The products are unique to the global pharmaceutical industry – highly cost-effective with proven efficacy; providing both patient and provider convenience; promoting adherence, while delivering superior clinical outcomes and economic benefits to all stakeholders. For more information, visit . Forward looking statements The information in this press release contains forward-looking statements including the prospective development, commercialization and regulatory approval in the U.S. and international markets. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors including the Company's ability to raise sufficient funds to bring new products to the global market. Contact: [email protected] SOURCE CardioPharma, Inc.

专利到期

2024-05-13

·米内网

中药创新龙头大爆发！22个独家产品热销，百亿市场大突破，6款1类新药上市可期

精彩内容5月11日，中药创新龙头企业以岭药业发布公告称，公司通过高新技术企业重新认定，将连续三年享受国家相关优惠政策。早前，公司对外公布了2023年业绩，营业收入连续三年保持在100亿元以上，中药1.1类新药通络明目胶囊获批，成功为以岭药业打开了五官科用药市场大门。目前，公司还有4款中药1类新药和2款化药1类新药在III期临床或报产阶段，上市可期。以岭药业手握22个独家中成药，8大产品在细分市场名列前茅，市场地位稳步提升。手握22个独家中成药，8大产品名列前茅在中成药板块，以岭药业已形成了独具优势的络病理论创新带动专利新药研发的科技核心竞争力，建立了具有自主知识产权的新药研发体系，创新能力居中药行业前列。米内网数据显示，目前以岭药业拥有22个独家中成药，涉及8个大类（12个亚类），多个产品在细分市场处于领先地位。表1：以岭药业的独家中成药来源：米内网中国上市药品（MID）数据库心脑血管是公司的拳头领域，2023年该类药物的营业收入占公司总营收的45%以上。其中通心络胶囊、参松养心胶囊和芪苈强心胶囊三个独家产品的治疗范围涵盖了最常见的缺血性心脑血管病、心律失常、心力衰竭三个适应症。表2：2023年三个独家产品在中成药心血管疾病用药市场的情况来源：米内网格局数据库在中国三大终端六大市场（统计范围见文末）中成药心血管疾病用药市场，以岭药业的参松养心胶囊、通心络胶囊、芪苈强心胶囊均上榜TOP10品牌，实力不容小觑。2023年在中国公立医疗机构终端（城市公立医院+县级公立医院+城市社区中心+乡镇卫生院），参松养心胶囊、通心络胶囊、芪苈强心胶囊的销售额增长率分别为9.62%、0.29%、4.02%，其中参松养心胶囊的品牌排名升上了1位；在中国城市实体药店终端，三大产品的品牌排名稳定，其中通心络胶囊的销售额保持正增长，增速为3.34%；在中国网上药店终端，参松养心胶囊的销售额增长率超过27%，通心络胶囊的销售额增长率超过19%，芪苈强心胶囊的销售额增长率为4%，市场潜力大爆发。呼吸系统类产品已成为以岭药业的“第二把交椅”，2023年该类药物的营业收入占公司总营收的32%以上。独家产品连花清瘟胶囊和连花清瘟颗粒是首次应用络病理论探讨外感温热病发病规律与治疗并指导研发的中药新药。2023年在中国公立医疗机构终端中成药感冒用药市场，连花清瘟颗粒为TOP1品牌，连花清瘟胶囊为TOP3品牌；在中国城市实体药店终端中成药感冒用药市场，连花清瘟胶囊为TOP2品牌，连花清瘟颗粒为TOP7品牌；在中国网上药店终端中成药感冒用药市场，连花清瘟胶囊为TOP1品牌，连花清瘟颗粒为TOP6品牌。此外，公司2020年获批上市的连花清咳片是以中医络病理论为指导、集合传统经典名方及临床实践研制的用于治疗急性气管-支气管炎的止咳祛痰平喘用药中药新药。2023年在中国公立医疗机构终端，连花清咳片的销售额增长率超过42%，在中国城市实体药店终端的销售额增长率超过11%，在中国网上药店终端的销售额增长率超过376%。连花清咳片在2023年11月转为非处方药，公司表示借助连花清瘟品牌及渠道，该产品快速打开了市场，销售呈现较好增长。在消化系统疾病领域，以岭药业的独家产品津力达颗粒是首次应用络病理论探讨消渴（糖尿病）发病规律与治疗所指导研发的用于治疗2型糖尿病的中药新药。2023年在中国公立医疗机构终端以及中国城市实体药店终端中成药糖尿病用药市场，津力达颗粒均为TOP2品牌，在中国网上药店终端中成药糖尿病用药市场是TOP5品牌，2023年的销售额增长率超过18%。以岭药业2021年在神经系统领域拿下了两款中药新药，益肾养心安神片是公司应用络病理论以经方为基础化裁研发的治疗失眠症的中药新药，解郁除烦胶囊是以汉代仲景经方化裁研发的治疗轻、中度抑郁症的中药新药。目前解郁除烦胶囊已闯出了好成绩，2023年在中国公立医疗机构终端中成药抗抑郁药市场为TOP5品牌，在中国城市实体药店终端中成药抗抑郁药市场为TOP10品牌，在中国网上药店终端中成药抗抑郁药市场为TOP17品牌。在泌尿系统领域，公司的独家产品夏荔芪胶囊是应用络病理论探讨前列腺疾病中医证治规律指导研发的中药新药。该产品2023年在中国公立医疗机构终端中成药前列腺用药市场为TOP7品牌，在中国城市实体药店终端中成药前列腺用药市场为TOP3品牌，在中国网上药店终端中成药前列腺用药市场为TOP11品牌。2024年4月9日NMPA官网显示，以岭药业提交了夏荔芪胶囊的中药保护初保申请，在相关政策保护下，优质的独家中成药有望继续实现腾飞。研发投入近10亿，8款中药新药来势汹汹据公司年报显示，以岭药业2023年的研发投入金额为9.35亿元，同比增长4.41%。公司的研发成果陆续显现，2023年成功拿下了1.1类新药通络明目胶囊，该新药是络病理论指导糖尿病视网膜病变治疗的中药新药，同时也是公司在中成药五官科用药市场的首个产品，具有积极意义，米内网数据显示，2023年中国三大终端六大市场中成药五官科用药的销售规模已超过140亿元，以岭药业已成功打开了新市场大门。近几年，公司通过强化中医药理论、人用经验、临床试验“三结合”的中药注册审评证据体系打造，不断提升研发产出效率、丰富研发产品阵列，目前有8款中药新药正在火热推进中。表3：以岭药业部分在研的重磅中药新药来源：公司年报、米内网综合数据库辛芪通鼻片是以岭药业在五官科领域的另一款中药1.1类新药，该新药用于持续性变应性鼻炎肺脾两虚证，在2023年11月提交了上市申请，目前正在审评审批中。年报资料显示，治疗慢性胆囊炎的柴黄利胆胶囊已完成Ⅲ期临床；米内网中国临床试验数据库显示，治疗类风湿关节炎的络痹通片在今年4月也完成了Ⅲ期临床；目前小儿连花清感颗粒正在Ⅲ期临床阶段，这3款中药1.1类新药离报产仅一步之遥，值得期待。柴芩通淋片正在II期临床阶段，第一例受试者已在今年1月成功入组；参蓉颗粒和藿夏感冒颗粒分别在今年1月、3月启动了II期临床，这3款中药1.1类新药将是公司下一批报产的重磅新药。2023年12月，以岭药业的中药2.2类新药连花清咳颗粒获批临床，该新药是连花清咳片的改良剂型，用于4至12岁儿童人群急性气管-支气管炎痰热壅肺证引起的咳嗽，后续有望为“连花”系列再添一员猛将。以岭药业的中药新药研发已做到了“申报一批、在研一批、储备一批”可持续发展，为公司业绩的稳定提升奠定了坚实的基础。公司表示，未来研发计划布局的方向包括大呼吸领域、内分泌领域、胃肠肝胆领域、妇科和儿科疾病领域，此外在五官科、免疫类疾病、类风湿关节炎、罕见病等方向的布局也将逐步完善。首款化药1类新药报产在即，集采产品排名飞升以岭药业的新药研发管线还伸向了化生药领域，目前已有5款新药进入临床阶段，其中用于术后疼痛的化药1.1类新药苯胺洛芬注射液已完成了III期临床，报产在即，该新药有望成为公司首个获批的化药1类新药。表4：以岭药业部分在研的重磅“化生”新药来源：公司年报、米内网综合数据库此外，抗肿瘤化药1类新药XY0206片也进入了III期临床阶段，值得期待；脑血管化药1类新药XY03-EA片正在II期临床阶段，公司在化生新药的研发上也遵循着“申报一批、在研一批、储备一批”的原则，有望为公司带来持续向好的力量。表5：以岭药业已过评/视同过评的产品注：*为按新分类获批视同过评来源：米内网中国申报进度（MED）数据库以岭药业通过国采进一步提升了仿制药的市场竞争力，公司在第三批、第五批以及第七批国采合共中标5个产品。2023年在中国公立医疗机构终端，以岭药业已成为了盐酸环丙沙星片的TOP1企业、卡托普利片的TOP2企业、单硝酸异山梨酯片的TOP3企业、盐酸二甲双胍片的TOP5企业，成绩亮眼。拿下12个ANDA文号，“共线产品”转报国内喜讯不断以岭药业的国际化之路也在快速推进，近几年硕果累累，针对美国市场目前已持有12个ANDA文号。公司在年报中提到，子公司以岭万洲与多家美国大型销售公司达成代理合作，加速推进产品在美国市场的销售，同时在全球范围内积极寻求与国外知名药企的深入合作，持续不断地引进新的ANDA产品，开拓全球药品市场，此外，公司还启动了进军加拿大和欧洲市场的战略部署。表6：以岭药业已获得的ANDA文号情况来源：公司年报、米内网美国FDA数据库值得注意的是，以岭药业已过评的产品中有3个是近几年按新分类获批的新品，公司表示，利用“欧美共线”申报的优先审评政策，把获得美国FDA批准的ANDA产品转报国内，可助力公司快速壮大仿制药产品线，目前来曲唑片、阿那曲唑片和塞来昔布胶囊已在国内顺利获批，后续将会推进更多欧美批文产品转报国内。资料来源：公司年报、米内网数据库等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至5月13日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

临床3期医药出海申请上市

100 项与卡托普利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00251	卡托普利	C09AA01	DB01197

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
原发性高血压	日本	Alfresa Pharma Corp.	1982-10-07
恶性高血压	日本	Alfresa Pharma Corp.	1982-10-07
肾血管性高血压	日本	Alfresa Pharma Corp.	1982-10-07
高血压肾病	日本	Alfresa Pharma Corp.	1982-10-07
左心室功能不全	美国	Strides Pharma Global Pte Ltd.	1981-04-06
糖尿病肾病	日本	Daiichi Sankyo Co., Ltd.	1980-01-01
心脏衰竭	日本	Daiichi Sankyo Co., Ltd.	1980-01-01
高血压	日本	Daiichi Sankyo Co., Ltd.	1980-01-01
心肌梗塞	日本	Daiichi Sankyo Co., Ltd.	1980-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	-	Kafrelsheikh University	2020-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03179163 (CTgov)	临床1/2期	原发性高血压	10	Captopril	遞憲範獵窪獵鑰築範觸(醖鹹夢顧憲艱鬱鹹鹹繭) = 艱憲簾範鹽壓觸繭鑰鏇糧範醖範齋襯廠構齋構 (網願製窪製糧網壓醖淵, 繭齋範衊範觸簾鹽製繭 ~ 構獵鑰鹹積簾鏇製願餘) 更多	-	2024-02-28
NCT01669434 (CTgov)	临床4期	低血压	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	憲鏇蓋膚遞願膚齋鏇餘(廠簾繭鑰餘鏇築鬱鹽艱) = 餘衊鑰膚鬱獵襯醖壓構鑰糧繭鹹餘醖窪網襯觸 (餘製鑰壓觸積蓋積餘製, 廠構膚淵繭獵鹹蓋齋選 ~ 艱衊觸鏇觸製構憲憲鬱) 更多	-	2017-12-11
				ACEI continuation (ACEI Continuation)	憲鏇蓋膚遞願膚齋鏇餘(廠簾繭鑰餘鏇築鬱鹽艱) = 蓋鹹淵糧網顧壓壓範膚鑰糧繭鹹餘醖窪網襯觸 (餘製鑰壓觸積蓋積餘製, 鏇範齋鏇淵鬱廠鹽繭觸 ~ 觸餘膚鹽構蓋糧醖憲窪) 更多
NCT00660309 (CTgov)	临床4期	2型糖尿病	45	Captopril+Aliskiren (Aliskiren)	淵積襯選窪夢顧醖糧簾(鹹壓獵廠網餘製糧糧選) = 艱衊糧顧網餘鹽選餘廠壓觸壓夢遞夢憲夢襯鏇 (憲獵醖鏇艱獵鹹顧糧夢, 鑰醖鬱鏇淵築積鹹夢網 ~ 繭網蓋餘鏇夢夢網壓憲) 更多	-	2012-08-29
				Captopril+Irbesartan (Irbesartan)	淵積襯選窪夢顧醖糧簾(鹹壓獵廠網餘製糧糧選) = 憲廠製艱製鑰鹽選鬱蓋壓觸壓夢遞夢憲夢襯鏇 (憲獵醖鏇艱獵鹹顧糧夢, 積糧齋窪製選簾憲齋遞 ~ 糧鹹艱餘憲齋蓋膚鑰醖) 更多
NCT00391846 (CTgov)	临床4期	心脏衰竭 \| 左心室收缩功能障碍	252	The Kansas City Cardiomyopathy Questionnaire (KCCQ)+Valsartan+Eplerenone+Ramipril+Trandolapril+Lisinopril+Captopril+Metoprolol succinate+Candesartan+Spironolactone+Enalapril+Carvedilol+Bisoprolol (Guided by NT-proBNP)	簾膚構蓋繭簾鏇廠觸範(鏇願膚願製壓鹽膚遞淵) = 鏇繭衊繭廠壓顧壓鬱齋衊鑰積築蓋廠鏇選醖夢 (壓製壓淵鹽廠窪鬱顧夢, 願糧願遞獵鏇繭簾範憲 ~ 餘選構齋鹹窪鹽觸餘網) 更多	-	2012-06-18
				The Kansas City Cardiomyopathy Questionnaire (KCCQ)+Valsartan+Eplerenone+Ramipril+Trandolapril+Lisinopril+Captopril+Metoprolol succinate+Candesartan+Spironolactone+Enalapril+Carvedilol+Bisoprolol (Not Guided by NT-proBNP)	簾膚構蓋繭簾鏇廠觸範(鏇願膚願製壓鹽膚遞淵) = 蓋淵齋窪糧糧鑰網繭鹽衊鑰積築蓋廠鏇選醖夢 (壓製壓淵鹽廠窪鬱顧夢, 鏇淵繭襯憲壓構構夢夢 ~ 築壓糧廠鑰齋繭範顧範) 更多
ARVO2012	N/A	糖尿病性视网膜病变	317	Captopril	製艱鹽齋襯觸夢窪艱糧(網築範艱願鏇夢蓋積簾) = 簾遞觸艱廠製製積構鹹鹽築鏇鏇鬱鏇鬱膚夢窪 (積積壓醖願積憲窪衊選 ) 更多	-	2012-03-01
				Vitamin C	製艱鹽齋襯觸夢窪艱糧(網築範艱願鏇夢蓋積簾) = 衊憲構範糧糧衊夢獵顧鹽築鏇鏇鬱鏇鬱膚夢窪 (積積壓醖願積憲窪衊選 ) 更多
ASN2010	N/A	2型糖尿病 \| 慢性肾病追加	-	Aliskiren 150 mg	餘憲範鑰網糧顧糧蓋膚(願壓範齋築夢憲簾選觸) = 鬱憲鑰構窪觸願鏇糧鏇鹽醖遞鹹築淵夢醖鹹積 (網網蓋餘壓醖廠鬱遞艱 ) 更多	不佳	2010-11-16
				Aliskiren 300 mg	餘憲範鑰網糧顧糧蓋膚(願壓範齋築夢憲簾選觸) = 壓壓壓齋蓋觸衊憲網顧鹽醖遞鹹築淵夢醖鹹積 (網網蓋餘壓醖廠鬱遞艱 ) 更多
ASN2010	N/A	骨髓移植排斥反应	-	Captopril	鑰鬱鹽顧齋齋構觸網觸(衊醖顧製衊鬱選構鹽顧) = 窪廠遞鏇製鏇鏇齋顧鹽鹹艱遞願艱餘鏇範獵淵 (選構衊鏇願範遞繭壓積 )	积极	2010-11-16
				Captopril	鑰鬱鹽顧齋齋構觸網觸(衊醖顧製衊鬱選構鹽顧) = 夢壓鏇網築鹽鏇糧餘窪鹹艱遞願艱餘鏇範獵淵 (選構衊鏇願範遞繭壓積 )
EULAR2005	N/A	肺纤维化	44	Bleomycin	鹽憲壓鏇築廠夢餘壓夢(積製窪衊鏇製製衊壓衊) = 壓顧簾夢獵遞膚獵餘顧淵壓鑰蓋構鬱積齋壓餘 (夢築鹹襯範淵淵獵壓襯 ) 更多	不佳	2005-06-08
				Dermatansulphate	鹽憲壓鏇築廠夢餘壓夢(積製窪衊鏇製製衊壓衊) = 膚夢衊壓淵淵淵遞憲艱淵壓鑰蓋構鬱積齋壓餘 (夢築鹹襯範淵淵獵壓襯 ) 更多
ARVO2005	N/A	糖尿病性视网膜病变	-	Captopril	鹹構夢襯糧觸鏇願築艱(鹹壓襯艱憲醖觸膚廠糧) = 選積壓夢鹹醖鑰夢艱積獵蓋鬱觸鑰鹹憲製範獵 (範蓋淵簾選壓鏇膚壓襯 )	-	2005-05-01
				Captopril	襯淵膚獵網遞鹹糧網願(鏇積顧膚蓋齋醖願積膚) = 構簾鏇選構鏇鏇蓋鏇網築網鹽襯衊鏇範鹽窪鹽 (窪襯淵願憲選構夢繭積 )
SAVE Investigators (Pubmed \| Br Dent J)	临床3期	心肌梗塞	2,231	Captopril	簾壓齋鬱積廠構繭顧窪(顧衊壓蓋齋窪遞積顧鑰) = 膚廠壓蓋積醖遞遞簾網築製蓋獵醖膚衊網鬱憲 (齋願鹹繭鏇齋衊淵餘獵 )	积极	1992-09-03
				Placebo	簾壓齋鬱積廠構繭顧窪(顧衊壓蓋齋窪遞積顧鑰) = 製艱築範鏇鹽膚顧範願築製蓋獵醖膚衊網鬱憲 (齋願鹹繭鏇齋衊淵餘獵 )